Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense® HER2 breast cancer Phase I first-in-human study.
Read the announcement.
Home » First In-human Study Update: Study Open for Enrolment
Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense® HER2 breast cancer Phase I first-in-human study.
Read the announcement.
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited
https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
We’re on a mission to make cancer more detectable.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance